Pathology of explanted pediatric hearts: An 11-year study. Population characteristics and implications for outcomes.
cardiac pathology
cardiomyopathy
congenital heart disease
explanted hearts
fibrosis
heart transplantation
homograft
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
25
02
2024
received:
12
09
2023
accepted:
03
03
2024
medline:
4
5
2024
pubmed:
4
5
2024
entrez:
4
5
2024
Statut:
ppublish
Résumé
As more pediatric patients become candidates for heart transplantation (HT), understanding pathological predictors of outcome and the accuracy of the pretransplantation evaluation are important to optimize utilization of scarce donor organs and improve outcomes. The authors aimed to investigate explanted heart specimens to identify pathologic predictors that may affect cardiac allograft survival after HT. Explanted pediatric hearts obtained over an 11-year period were analyzed to understand the patient demographics, indications for transplant, and the clinical-pathological factors. In this study, 149 explanted hearts, 46% congenital heart defects (CHD), were studied. CHD patients were younger and mean pulmonary artery pressure and resistance were significantly lower than in cardiomyopathy patients. Twenty-one died or underwent retransplantation (14.1%). Survival was significantly higher in the cardiomyopathy group at all follow-up intervals. There were more deaths and the 1-, 5- and 7-year survival was lower in patients ≤10 years of age at HT. Early rejection was significantly higher in CHD patients exposed to homograft tissue, but not late rejection. Mortality/retransplantation rate was significantly higher and allograft survival lower in CHD hearts with excessive fibrosis of one or both ventricles. Anatomic diagnosis at pathologic examination differed from the clinical diagnosis in eight cases. Survival was better for the cardiomyopathy group and patients >10 years at HT. Prior homograft use was associated with a higher prevalence of early rejection. Ventricular fibrosis (of explant) was a strong predictor of outcome in the CHD group. We presented several pathologic findings in explanted pediatric hearts.
Sections du résumé
BACKGROUND
BACKGROUND
As more pediatric patients become candidates for heart transplantation (HT), understanding pathological predictors of outcome and the accuracy of the pretransplantation evaluation are important to optimize utilization of scarce donor organs and improve outcomes. The authors aimed to investigate explanted heart specimens to identify pathologic predictors that may affect cardiac allograft survival after HT.
METHODS
METHODS
Explanted pediatric hearts obtained over an 11-year period were analyzed to understand the patient demographics, indications for transplant, and the clinical-pathological factors.
RESULTS
RESULTS
In this study, 149 explanted hearts, 46% congenital heart defects (CHD), were studied. CHD patients were younger and mean pulmonary artery pressure and resistance were significantly lower than in cardiomyopathy patients. Twenty-one died or underwent retransplantation (14.1%). Survival was significantly higher in the cardiomyopathy group at all follow-up intervals. There were more deaths and the 1-, 5- and 7-year survival was lower in patients ≤10 years of age at HT. Early rejection was significantly higher in CHD patients exposed to homograft tissue, but not late rejection. Mortality/retransplantation rate was significantly higher and allograft survival lower in CHD hearts with excessive fibrosis of one or both ventricles. Anatomic diagnosis at pathologic examination differed from the clinical diagnosis in eight cases.
CONCLUSIONS
CONCLUSIONS
Survival was better for the cardiomyopathy group and patients >10 years at HT. Prior homograft use was associated with a higher prevalence of early rejection. Ventricular fibrosis (of explant) was a strong predictor of outcome in the CHD group. We presented several pathologic findings in explanted pediatric hearts.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14742Informations de copyright
© 2024 The Authors. Pediatric Transplantation published by Wiley Periodicals LLC.
Références
Mayer JE, Perry S, O'Brien P, et al. Orthotopic heart transplantation for complex congenital heart disease. J Thorac Cardiovasc Surg. 1990;99(3):484‐492.
Zangwill S. Five decades of pediatric heart transplantation: challenges overcome, challenges remaining. Curr Opin Cardiol. 2017;32(1):69‐77.
Khush KK, Hsich E, Potena L, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: thirty‐eighth adult heart transplantation report ‐ 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1035‐1049.
Singh TP, Cherikh WS, Hsich E, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: twenty‐fourth pediatric heart transplantation report ‐ 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1050‐1059.
Dipchand AI, Naftel DC, Feingold B, et al. Outcomes of children with cardiomyopathy listed for transplant: a multi‐institutional study. J Heart Lung Transplant. 2009;28(12):1312‐1321.
Rossano JW, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: twenty‐first pediatric heart transplantation report‐2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1184‐1195.
Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi‐institutional study. Circulation. 2006;114(4):273‐280.
Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol. 2009;54(2):160‐165.
Davies RR, Sorabella RA, Yang J, Mosca RS, Chen JM, Quaegebeur JM. Outcomes after transplantation for "failed" Fontan: a single‐institution experience. J Thorac Cardiovasc Surg. 2012;143(5):1183‐1192 e1184.
Everitt MD, Boyle GJ, Schechtman KB, et al. Early survival after heart transplant in young infants is lowest after failed single‐ventricle palliation: a multi‐institutional study. J Heart Lung Transplant. 2012;31(5):509‐516.
Schumacher KR, Almond C, Singh TP, et al. Predicting graft loss by 1 year in pediatric heart transplantation candidates: an analysis of the pediatric heart transplant study database. Circulation. 2015;131(10):890‐898.
Burstein DS, Li Y, Getz KD, et al. Mortality, resource utilization, and inpatient costs vary among pediatric heart transplant indications: a merged data set analysis from the united network for organ sharing and pediatric health information systems databases. J Card Fail. 2019;25(1):27‐35.
Mills RM, Naftel DC, Kirklin JK, et al. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant. 1997;16(8):813‐821.
Gossett JG, Canter CE, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multi‐institutional study. J Heart Lung Transplant. 2010;29(6):625‐632.
Everitt MD, Pahl E, Schechtman KB, et al. Rejection with hemodynamic compromise in the current era of pediatric heart transplantation: a multi‐institutional study. J Heart Lung Transplant. 2011;30(3):282‐288.
Pahl E, Naftel DC, Canter CE, Frazier EA, Kirklin JK, Morrow WR. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients‐ a multi‐institutional study. J Heart Lung Transplant. 2001;20(3):279‐287.
Webber SA, Naftel DC, Parker J, et al. Late rejection episodes more than 1 year after pediatric heart transplantation: risk factors and outcomes. J Heart Lung Transplant. 2003;22(8):869‐875.
Daly KP, Chandler SF, Almond CS, et al. Antibody depletion for the treatment of crossmatch‐positive pediatric heart transplant recipients. Pediatr Transplant. 2013;17(7):661‐669.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405‐424.
Pradegan N, Vida VL, Geva T, et al. Myocardial histopathology in late‐repaired and unrepaired adults with tetralogy of Fallot. Cardiovasc Pathol. 2016;25(3):225‐231.
Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome: consensus‐derived diagnosis and care recommendations. J Pediatr. 2016;178:24‐33.e2.
Rossano JW, Dipchand AI, Edwards LB, et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth pediatric heart transplantation Report‐2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1185‐1195.
O'Connor MJ, Lind C, Tang X, et al. Persistence of anti‐human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. J Heart Lung Transplant. 2013;32(4):390‐397.
Crossland DS, Jansen K, Parry G, et al. Outcome following heart transplant assessment in adults with congenital heart disease. Heart. 2019;105(22):1741‐1747.
Donovan DJ, Richmond ME, Bacha EA, Addonizio LJ, Zuckerman WA. Association between homograft tissue exposure and allosensitization prior to heart transplant in patients with congenital heart disease. Pediatr Transplant. 2022;26(3):e14201.
Shaddy RE, Fuller TC, Anderson JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg. 2004;77(5):1734‐1739. discussion 1739.
Meyer SR, Nagendran J, Desai LS, et al. Decellularization reduces the immune response to aortic valve allografts in the rat. J Thorac Cardiovasc Surg. 2005;130(2):469‐476.
Madden R, Lipkowitz G, Benedetto B, Kurbanov A, Miller M, Bow L. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. Am J Kidney Dis. 2002;40(6):1240‐1243.
Moscarello T, Moayedi Y, Caleshu C, Khush K, Purewal S, Teuteberg J. You can't find what you aren't looking for: over half of heart transplant patients have moderate or strong likelihood of genetic disease. J Heart Lung Transplant. 2020;39:S166.
Pietra BA, Kantor PF, Bartlett HL, et al. Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy. Circulation. 2012;126(9):1079‐1086.
Wienecke LM, Cohen S, Bauersachs J, Mebazaa A, Chousterman BG. Immunity and inflammation: the neglected key players in congenital heart disease? Heart Fail Rev. 2022;27(5):1957‐1971.
Gordon B, Gonzalez‐Fernandez V, Dos‐Subira L. Myocardial fibrosis in congenital heart disease. Front Pediatr. 2022;10:965204.
Forte E, Panahi M, Baxan N, et al. Type 2 MI induced by a single high dose of isoproterenol in C57BL/6J mice triggers a persistent adaptive immune response against the heart. J Cell Mol Med. 2021;25(1):229‐243.
Sintou A, Mansfield C, Iacob A, et al. Mediastinal lymphadenopathy, class‐switched auto‐antibodies and myocardial immune‐complexes during heart failure in rodents and humans. Front Cell Dev Biol. 2020;8:695.
Adamo L, Rocha‐Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269‐285.